somewordstoolate/Q2CRBench-3 huggingface dataset:
Reference: Treatment of Atrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry Subic A, Cermakova P, Religa D, Han S, von Euler M, Kareholt I, Johnell K, Fastbom J, Bognandi L, Winblad B, Kramberger MG, Eriksdotter M, Garcia-Ptacek S J Alz Dis 2018;61(3):1119-1128
Study design: Observational Study
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Total study population: 3724
Patients not treated: 2181
Baseline age (mean (SD)): 82.3 (6.5) (patients without treatment); 80.8 (5.8) (patients with treatment)
Baseline MMSE (median (IQR)): 21 (7); (patients without treatment); 23 (5) (patients with treatment)
Reference: Quetiapine to treat agitation in dementia: a randomized double-blind placebo-controlled study Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA. Curr Alzheimer Res 2007;4(1):81-93
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 333
Age placebo: 83.2 (7.2)
Age intervention 1: 83.5 (8.0) 
Age intervention 2: 83 (7.9)
MMSE placebo: 5.6 (3.6) 
MMSE intervention 1: 4.8 (4.0) 
MMSE intervention 2: 5.5 (4)
Reference: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind randomized placebo-controlled trial The HGEU Study Group. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, al et. Arch Gen Psychiatry; 200057(10):968-976
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 206
Age placebo: 81.4 (6.7)
Age intervention 1: 82.9 (6.5)
Age intervention 2: 83.6 (6.5)
Age intervention 3: 83 (6.7)
MMSE placebo: 7.3 (6.3)
MMSE intervention 1: 7.3 (6.5)
MMSE intervention 2: 6.6 (6.7)
MMSE intervention 3: 6.4 (6.7)
Reference: Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail M, Lebowitz BD, Lyketsos CG, Ryan J, Stroup T, Sultzer DL, Weintraub D, Lieberman JA.  NEJM 2006;355(15): 1525-1538
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 421
Age placebo: 77.3 (7.1)
Age intervention 1: 78.8 (7.3)
Age intervention 2: 77.3 (8.7)
Age intervention 3: 78.4 (7.1)
MMSE placebo: 14.7 (5.8)
MMSE intervention 1: 15.0 (5.4)
MMSE intervention 2: 14.9 (6.1)
MMSE intervention 3: 15.7 (6.1)
Reference: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everatt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R. BMJ 2005;330(7496):874
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 62
Age placebo: 83.0 (6.8)
Age intervention: 84.3 (7.8)
SIB placebo: 59.4 (30.5)
SIB intervention: 69.0 (28.2)
Reference: A randomized placebo-controlled trial of risperidone for the treatment of aggression agitation and psychosis of dementia. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman FJ Clin Psych 2003;64(2):134-43
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 345
Age placebo: 82.7 (0.64)
Age intervention: 83.2 (0.51)
MMSE placebo: 5.1 (0.5)
MMSE intervention: 5.78 (0.46)
Reference: Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS. Am J Psychiatry 2008;165(7):844-854
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 421
Age placebo: 77.3 (7.1)
Age intervention 1: 78.8 (7.3)
Age intervention 2: 77.3 (8.7)
Age intervention 3: 78.4 (7.1)
MMSE placebo: 14.7 (5.8)
MMSE intervention 1: 15.0 (5.4)
MMSE intervention 2: 14.9 (6.1)
MMSE intervention 3: 15.7 (6.1)
Reference: Quetiapine for agitation or psychosis in patients with dementia and parkinsonism Kurlan R, Cummings J, Raman R, Thal L. Neurology 2007;68(17):1356-1363
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 40 (AD patients: 8; PD+dementia 9; LBD: 23)
Age placebo: 74.1 (6.1) 
Age intervention: 73.5 (5.8)
MMSE placebo: 17.2 (5.9)
MMSE intervention: 19.2 (6.5)
Reference: A randomized double-blind crossover comparison of risperidone and haloperidol in Korean Dementia patients with behavioral disturbances Suh GH, Son HG, Ju YS, Jcho KH, Yeon BK, Shin YM, Kee BS, Choi SK. Am J Geriatr Psych 2004;12(5):509-516
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 120 AD: 79; VaD: 34; Mixed AD-VaD: 7
Age Haloperidol: 81.5 (7.7) Haloperidol-to-risperidone
Age intervention: 80.4 (5.6) Risperidone-to-haloperidol
MMSE Haloperidol: 9.4 (5.2) MMSE korean version
MMSE intervention: 9.7 (7.5)
Reference: Olanzapine versus Haloperidol in the Treatment of Agitation in Elderly Patients with Dementia: Results of a Randomized Controlled Double-Blind Trial. Verhey FR, Verkaaik M, Lousberg R. Dementia Geriatric Cogn Dis 2005;21(1):1-8
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 58
Age haloperidol: 82.4
Mean age intervention: 83.3 (8.1)
Mean MMSE Haloperidol: 10.9 (7.2)
Mean MMSE intervention: 10 (7.7)
Reference: A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Chan W, Lam LC, Choy CN, Leung VP, Li S, Chiu H. International J Geriatr Psych 2001;16(12):1156-1162 
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 120
Mean age Haloperidol: 80.8 (6.8)
Mean age intervention: 80.2 (9.7)
Mean MMSE Haloperidol: 8.2 (5)
Mean MMSE intervention: 7.9 (6)
Reference: A randomized trial of risperidone placebo and haloperidol for behavioral symptoms of dementia. De Deyn PP Rabheru K Rasmussen A Bocksberger JP Dautzenberg PLJ Eriksson S et al. Neurology 1999;53(5):946–946
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 230 Randomized to either haloperidol or risperidone
Mean age Haloperidol: 82 (56/97) Median (min/max)
Mean age intervention: 81 (68/97) Median (min/max)
Mean MMSE Haloperidol: 7.9 (6.1- 9.2) 
Mean MMSE intervention: 8.6 (7.5 - 9.8)
Reference: Stopping antipsychotic drug therapy in demented nursing home patients: a randomized placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS). Ruths S, Straand J, Nygaard HA, Aarsland D International J Geriatr Psych 2008;23(9):889-95
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 55
Age continuation: 84.6 (5.9)
Age discontinuation: 83.6 (8.1)
MMSE continuation: Not reported
MMSE discontinuation: Not reported
Baseline daily doses (median (range)): risperidone 1.0 (0.5–2.0) mg, haloperidol 1.0 (0.5–1.5) mg, or olanzapine 5.0 mg (2.5–5.0)
Reference: Withdrawal of neuroleptic medication from institutionalized dementia patients: results from a double-blind baseline-treatment-controlled pilot study. Bridges-Parlet S, Knopman D, Seffes S. J Geriatr Psych Neurol 1997;10(3):119-126
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 36
Age continuation: 83.9 (6.1)
Age discontinuation: 81.7 (6)
Baseline MMSE continuation: Not reported (Number of participants with a score of 0 on the MMSE was reported: Discontinued: 19; Continued: 11)
Baseline MMSE discontinuation: Not reported (Number of participants with a score of 0 on the MMSE was reported: Discontinued: 19; Continued: 11)
Baseline daily doses: Total daily dosage-chlorpromazine equivalents: Discont.: 41.1 (21.7); cont.: 51.7 (25.5)
Reference: Relapse risk after discontinuation of risperidone in Alzheimer's disease. Devanand D, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Levin B, NEJM 2012;367(16):1497-1507
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 110
Age continuation: 80.7 (±7.9)
Age partly discontinuation: 79.1 (±8.0) ( The study had a lead-in period (phase A), where patients with psychosis or aggression/agitation were treated with risperidone. Responders were then included in phase B (discontinuation trial), whereas non-responders were excluded. Phase B was further divided into 2 phases. For the first phase, the responders were divided into 3 groups, 2 treated with antipsychotics, and the 3rd randomized to placebo (discontinuation). Data extracted for the present analysis is for the first phase of phase B. In the second phase, one of the groups treated with antipsychotics, were also switched to placebo.)
Age discontinuation: 80.3 (±7.7)
Baseline MMSE continuation: 13.4 (±6.6)
Baseline MMSE partly discontinuation: 13.6 (±6.7) ( The study had a lead-in period (phase A), where patients with psychosis or aggression/agitation were treated with risperidone. Responders were then included in phase B (discontinuation trial), whereas non-responders were excluded. Phase B was further divided into 2 phases. For the first phase, the responders were divided into 3 groups, 2 treated with antipsychotics, and the 3rd randomized to placebo (discontinuation). Data extracted for the present analysis is for the first phase of phase B. In the second phase, one of the groups treated with antipsychotics, were also switched to placebo.)
Baseline MMSE discontinuation: 15.5 (±6.6)
Baseline daily doses (mean (SD)): Risperidone: 0.97(±0.74 mg)
Reference: A 3-month randomized placebo-controlled neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E al et. J Clin Psych 2004;65(1):114-119
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 100
Age continuation: 83.1 (7.1)
Age discontinuation: 83.6 (9.3)
Baseline MMSE continuation (median (range): 2.5 (0-23)
Baseline MMSE discontinuation (median (range): 3 (0-21)
Baseline daily doses (median (range): Risperidone 1.3 (0.7); Thioridazine 38 (26.2); Haloperidol: 0.9 (0.4); Trifluoperazine: 3.0 (1.4); Chlorpromazine: 20 (Only one patient)
Reference: The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, Gill R, Juszczak E, Yu LM, Jacoby R. Lancet Neurol 2009;8(2):151-157
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 165
Baseline age continuation: 84.8 (7.0)
Baseline age discontinuation: 84.9 (6.1)
Baseline MMSE continuation: 11 (6) (Reported for standardized MMSE)
Baseline MMSE discontinuation: 11 (5) (Reported for standardized MMSE)
Baseline daily doses (median (range): Not reported (No. of patients on various antipsychotics (numbers are continue/discontinue): Chlorpromazine High 0/1 Very low/low 1/1; Haloperidol High 1/0; Very low/low 22/20; Olanzapine: High 0/2 Very low/low 4/3; Promazine: High 0/0 Very low/low 0/2; Quetiapine: High 0/0 Very low/low 1/3; Risperidone High 9/12 Very low/low 43/37; Thioridazine High 0/0 Very low/low 2/0; Trifluoperazine High 0/1 Very low/low 0/0)
Reference: A 6-month randomized double-blind placebocontrolled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. Devanand D, Pelton G, Cunqueiro K, Sackeim HA, Marder K. International J Geriatr Psych 2011;26(9):937–43
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 20
Baseline age continuation: 75.0 (8.0) (Pooled mean for all responders.)
Baseline age discontinuation: N/A
Baseline MMSE continuation: 12.3 (6.3) (Pooled mean for all responders.)
Baseline MMSE discontinuation: N/A
Baseline daily doses (median (range): 1.53 mg (0.9) (Pooled mean for all responders.)
Reference: A randomized placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. van Reekum R, Clarke D, Conn D, Hermann N, Eryavec G, Cohen T, Ostrander L. International Psychogeriatrics 2002;14(2):197-210
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 34
Age continuation: 82.9 (6.9)
Age discontinuation: 84.4 (4.6)
MMSE continuation: 6.3 (7.6)
MMSE discontinuation: 8.8 (8.6)
Baseline daily doses: Total daily dosage-chlorpromazine equivalent: Discont. 24.9 (15.9), Cont. 34.3 (13.6)
Reference: A randomised blinded placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial). Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, Kossakowski K, Yu LM, Juszczak E. PLoS Med 2008;5(4):0587-0599
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 165
Baseline age continuation: 84.8 (7.0)
Baseline age discontinuation: 84.9 (6.1)
Baseline MMSE continuation: 11 (6) (Data extracted at 12 months)
Baseline MMSE discontinuation: 11 (5) (Data extracted at 12 months)
Baseline daily doses (median (range): Not reported (Reported for standardized MMSE)
Reference: Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia. Chibnall JT, Tait RC, Harman B, Luebbert RA. J Am Geriatr Soc 2005;53(11):1921-1929
Study design: Randomized Controlled Trial
Guideline evidence base: 2020 EAN Dementia
Study characteristics:
Number of patients randomized: 25
Mean age placebo-first: Not reported
Mean age intervention-first: Not reported
MMSE placebo-first: Not reported
Mean MMSE intervention-first: Not reported (For total sample mean age was 85.9 yrs (SD: 7.4).)
Reference: Dhir V, Singla M, Gupta N, Goyal P, Sagar V, Sharma A, et al. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis. Clinical Therapeutics. 2014;36(7):1005.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Mueller RBea. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine. 2019;8.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis care & research. 2013;65(9):1401.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Verstappen SM, Jacobs JW, Veen MJVD, Heurkens AH, Schenk Y, Borg EJt, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the Rheumatic Diseases. 2007;66(11):1443.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Verstappen SMB, M. F.; et. al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis BMJ. 2010;69(6):1044-8.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Islam MS, Haq SA, Islam MN, Azad AK, Islam MA, Barua. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Medical Journal: MMJ. 2013;22(3):483.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Lopez-Olivo MAT, J.H; Martinez-Lopez, J.A.; Pollono, E.N.; Cueto, J.P.; Gonzales-Crespo, M.R.; Fulton, S.; Suarez-Almazor, M.E. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898.
Study design: SYSTEMATIC_REVIEW
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Archives of Internal Medicine. 1999;159(21):2542.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmullerr G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatology International. 2007;27(10):975.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Fleischmann R. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. The Lancet. 2017;390(10093):457.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Kaneko Y AT, Tanaka Y, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). BMJ. 2016;75:1917-23.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Annals of the Rheumatic Diseases. 2009;68(7):1146.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Capell HA. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Annals of the Rheumatic Diseases. 2007;66(2):235.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.[Erratum appears in Arthritis Rheum. 2008 Mar;58(3):887]. Arthritis & Rheumatism. 2006;54(9):2817.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: van Riel PL. Efficacy and safely of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Annals of the Rheumatic Diseases. 2006;65(11):1478.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, Riel PV. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Annals of the Rheumatic Diseases. 2005;64(1):44.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: van Riel PL. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. Annals of the Rheumatic Diseases. 2008;67(8):1104.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Breedveld FA, S.; Yin, M.; et. al. Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response. J Clin Pharmacol. 2007;47:1119-28.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. 1998;41(9):1552.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Brown S, Everett CC, Naraghi. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Health Technology Assessment (Winchester, England). 2018;22(34):1.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Santos-Faria D. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor (TNFi) in rheumatoid arthritis patients who discontinued a first TNFi. ÓRGÃO OfICIAL dA SOCIEdAdE PORTUGUESA dE REUMATOLOGIA. 2019;44:103-13.
Study design: Observational Study
Guideline evidence base: 2021 ACR RA
Study characteristics:
Reference: Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 2007;66(7):893.
Study design: Randomized Controlled Trial
Guideline evidence base: 2021 ACR RA
Study characteristics: